• NuCana's management commentary reported a nine-month net loss through September 30, 2026, of £8.55 million, versus £26.87 million a year earlier.
• The improvement reflected lower expenses; prior-year results included £12.65 million in noncash derivative revaluation losses.
• Research and development expenses fell to £6.24 million, primarily reflecting a £4.2 million reduction in share-based payment expenses.
• Third-quarter net loss widened to £1.61 million from £281,000, reflecting the absence of prior-year insurance proceeds and ADR depositary contributions.
• Cash and cash equivalents declined to £18.3 million at September 30, 2026, from £24.3 million at December 31, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NuCana plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-458393), on November 12, 2026, and is solely responsible for the information contained therein.